Henrietta Venter

Dr. Henrietta Venter

The University of South Australia
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2014 in Nature
Verified
Journal Article
Open access
PDF file
DDDijun Du
Dijun Du
ZWzhao wang
zhao wang
NJNathan R. James
Nathan R. James
JVJarrod E. Voss
Jarrod E. Voss
EKEwa Klimont
Ewa Klimont
BLBonaventura F Luisi
Bonaventura F Luisi
Many bacteria are able to survive in the presence of antibiotics in part because they possess pumps that can remove a broad range of small molecules; here, the structure of one such pump, AcrAB–TolC, is determined using X-ray crystallography and cryo-electron microscopy. Many bacteria are able to survive in the presence of antibiotics and other toxic compounds because they possess versatile energy-dependent transmembrane pumps. For example, the AcrAB–TolC efflux pump, which spans the inner and outer membranes of the bacterium, is able to transport a broad range of structurally unrelated small molecules/drugs out of some Gram-negative bacteria. The pump is comprised of an outer-membrane channel (TolC), a secondary transporter (AcrB; located in the inner membrane), and AcrA, a periplasmic protein that acts as a bridge for these two integral membrane proteins. In this paper, the authors solve an X-ray crystal structure of AcrB bound to AcrZ (a small protein that appears to alter the substrate preferences of AcrB) and a cryo-EM structure of the entire 771 kDa efflux pump. The capacity of numerous bacterial species to tolerate antibiotics and other toxic compounds arises in part from the activity of energy-dependent transporters. In Gram-negative bacteria, many of these transporters form multicomponent ‘pumps’ that span both inner and outer membranes and are driven energetically by a primary or secondary transporter component1,2,3,4,5,6,7. A model system for such a pump is the acridine resistance complex of Escherichia coli1. This pump assembly comprises the outer-membrane channel TolC, the secondary transporter AcrB located in the inner membrane, and the periplasmic AcrA, which bridges these two integral membrane proteins. The AcrAB–TolC efflux pump is able to transport vectorially a diverse array of compounds with little chemical similarity, thus conferring resistance to a broad spectrum of antibiotics. Homologous complexes are found in many Gram-negative species, including in animal and plant pathogens. Crystal structures are available for the individual components of the pump2,3,4,5,6,7 and have provided insights into substrate recognition, energy coupling and the transduction of conformational changes associated with the transport process. However, how the subunits are organized in the pump, their stoichiometry and the details of their interactions are not known. Here we present the pseudo-atomic structure of a complete multidrug efflux pump in complex with a modulatory protein partner8 from E. coli. The model defines the quaternary organization of the pump, identifies key domain interactions, and suggests a cooperative process for channel assembly and opening. These findings illuminate the basis for drug resistance in numerous pathogenic bacterial species.

28 April 2015 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
Henrietta VenterHenrietta Venter
Henrietta Venter
RMRumana Mowla
Rumana Mowla
TOThelma Ohene-Agyei
Thelma Ohene-Agyei
SMShutao Ma
Shutao Ma
Drug efflux protein complexes confer multidrug resistance on bacteria by transporting a wide spectrum of structurally diverse antibiotics. Moreover, organisms can only acquire resistance in the presence of an active efflux pump. The substrate range of drug efflux pumps is not limited to antibiotics, but it also includes toxins, dyes, detergents, lipids and molecules involved in quorum sensing; hence efflux pumps are also associated with virulence and biofilm formation. Inhibitors of efflux pumps are therefore attractive compounds to reverse multidrug resistance and to prevent the development of resistance in clinically relevant bacterial pathogens. Recent successes on the structure determination and functional analysis of the AcrB and MexB components of the AcrAB-TolC and MexAB-OprM drug efflux systems as well as the structure of the fully assembled, functional triparted AcrAB-TolC complex significantly contributed to our understanding of the mechanism of substrate transport and the options for inhibition of efflux. These data, combined with the well-developed methodologies for measuring efflux pump inhibition, could allow the rational design and subsequent experimental verification of potential efflux pump inhibitors. In this review we will explore how the available biochemical and structural information can be translated into the discovery and development of new compounds that could reverse drug resistance in Gram-negative pathogens. The current literature on efflux pump inhibitors will also be analysed and the reasons why no compounds have yet progressed into clinical use will be explored.

28 February 2017 in Essays in Biochemistry
Verified
Journal Article
Closed access
PDF file
MAMohsen Arzanlou
Mohsen Arzanlou
WCWern Chai
Wern Chai
Henrietta VenterHenrietta Venter
Henrietta Venter
Gram-negative bacteria are responsible for a large proportion of antimicrobial-resistant infections in humans and animals. Among this class of bacteria are also some of the most successful environmental organisms. Part of this success is their adaptability to a variety of different niches, their intrinsic resistance to antimicrobial drugs and their ability to rapidly acquire resistance mechanisms. These mechanisms of resistance are not exclusive and the interplay of several mechanisms causes high levels of resistance. In this review, we explore the molecular mechanisms underlying resistance in Gram-negative organisms and how these different mechanisms enable them to survive many different stress conditions.

5 July 2009 in Nature Methods
Verified
Journal Article
Closed access
PDF file
NBNelson P Barrera
Nelson P Barrera
SIShoshanna C Isaacson
Shoshanna C Isaacson
MZMin Zhou
Min Zhou
VBVassiliy Bavro
Vassiliy Bavro
AWAlex Welch
Alex Welch
CRCarol V Robinson
Carol V Robinson

1 June 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Tavan JanvilisriTavan Janvilisri
Tavan Janvilisri
Henrietta VenterHenrietta Venter
Henrietta Venter
SSSanjay Shahi
Sanjay Shahi
GRGalya Reuter
Galya Reuter
LBLekshmy Balakrishnan
Lekshmy Balakrishnan
HVHendrik W. van Veen
Hendrik W. van Veen
The human breast cancer resistance protein (BCRP, also know as ABCG2, MXR, or ABCP) is one of the more recently discovered ATP-binding cassette (ABC) transporters that confer resistance on cancer cells by mediating multidrug efflux. In the present study, we have obtained functional expression of human BCRP in the Gram-positive bacterium Lactococcus lactis. BCRP expression conferred multidrug resistance on the lactococcal cells, which was based on ATP-dependent drug extrusion. BCRP-mediated ATPase and drug transport activities were inhibited by the BCRP-specific modulator fumitremorgin C. To our knowledge these data represent the first example of the functional expression of a mammalian ABC half-transporter in bacteria. Although members of the ABCG subfamily (such as ABCG1 and ABCG5/8) have been implicated in the transport of sterols, such a role has not yet been established for BCRP. Interestingly, the BCRP-associated ATPase activity in L. lactis was significantly stimulated by (i) sterols including cholesterol and estradiol, (ii) natural steroids such as progesterone and testosterone, and (iii) the anti-estrogen anticancer drug tamoxifen. In addition, BCRP mediated the efflux of [3H]estradiol from lactococcal cells. Our findings suggest that BCRP may play a role in the transport of sterols in human, in addition to its ability to transport multiple drugs and toxins.

1 September 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
GRGalya Reuter
Galya Reuter
Tavan JanvilisriTavan Janvilisri
Tavan Janvilisri
Henrietta VenterHenrietta Venter
Henrietta Venter
SSSanjay Shahi
Sanjay Shahi
LBLekshmy Balakrishnan
Lekshmy Balakrishnan
HVHendrik W. van Veen
Hendrik W. van Veen
LmrA is an ATP binding cassette (ABC) multidrug transporter in Lactococcus lactis that is a structural and functional homologue of the human multidrug resistance P-glycoprotein MDR1 (ABCB1). LmrA is also homologous to MsbA, an essential ABC transporter in Escherichia coli involved in the trafficking of lipids, including Lipid A. We have compared the substrate specificities of LmrA and MsbA in detail. Surprisingly, LmrA was able to functionally substitute for a temperature-sensitive mutant MsbA in E. coli WD2 at non-permissive temperatures, suggesting that LmrA could transport Lipid A. LmrA also exhibited a Lipid A-stimulated, vanadate-sensitive ATPase activity. Reciprocally, the expression of MsbA conferred multidrug resistance on E. coli. Similar to LmrA, MsbA interacted with photoactivatable substrate [3H]azidopine, displayed a daunomycin, vinblastine, and Hoechst 33342-stimulated vanadate-sensitive ATPase activity, and mediated the transport of ethidium from cells and Hoechst 33342 in proteoliposomes containing purified and functionally reconstituted protein. Taken together, these data demonstrate that MsbA and LmrA have overlapping substrate specificities. Our observations imply the presence of structural elements in the recently published crystal structures of MsbA in E. coli and Vibrio cholera (Chang, G., and Roth, C. B. (2001) Science 293, 1793–1800; Chang, G. (2003) J. Mol. Biol. 330, 419–430) that support drug-protein interactions and suggest a possible role for LmrA in lipid trafficking in L. lactis.